As of November 6, 2026, Acadia Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 1, 2026 to October 23, 2026, naming 1 departure. The latest filing names Z. Thompson, leaving (Form 8-K, October 23, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Acadia Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Acadia Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-01 to 2026-10-23. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Acadia Pharmaceuticals Inc files it.
Also on the record for Acadia Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.3% of the class | 5%+ stakes | Source |
| April 28, 2026 | Stake report, Schedule 13G, by Vanguard Portfolio Management | 5.15% of the class | 5%+ stakes | Source |
| March 26, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| February 26, 2026 | Stake report, Schedule 13D/A, by Baker Bros. Advisors LP | 25.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by RTW Investments, LP | 4.2% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Acadia Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Acadia Pharmaceuticals Inc and the records around it.
Acadia Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Baker Bros. Advisors LP also filed stake reports on 25 other companies: Madrigal Pharmaceuticals, Inc. (Nov 2026), Kodiak Sciences Inc. (Sep 2026), BeOne Medicines Ltd. (Sep 2026)
- RTW Investments, LP also filed stake reports on 43 other companies: CG Oncology, Inc. (Aug 2026), iRhythm Holdings, Inc. (Aug 2026), Kailera Therapeutics, Inc. (Aug 2026)
- STATE STREET CORPORATION also filed stake reports on 343 other companies: TRADE DESK INC/THE (Oct 2026), CENTRUS ENERGY CORP (Sep 2026), ALLEGION PLC (Aug 2026)
Watch Acadia Pharmaceuticals Inc
Get an email when Acadia Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Acadia Pharmaceuticals Inc?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Acadia Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Acadia Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-23 | Reported | not named in the filing | 8-K, 2026-10-23 | ||
| 2026-05-01 | Out | 8-K, 2026-05-01 |
New leaders reset buying decisions — get the Full Report on Acadia Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Acadia Pharmaceuticals Inc, with the record behind each one.
Find candidates like senior executive at Acadia Pharmaceuticals IncEvery change, in the filing's words
Reported
Departure Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- As of October 23, 2026, Dr. Thompson will no longer serve as an employee of the Company or function in her former role as Head of Research and Development.
- Also, effective October 23, 2026, Dr Thompson will be retained as a consultant by the Company and intends to provide limited consulting services to the Company through December 31, 2026.
- The Company is in the process of identifying Dr. Thompson's replacement.
- Many factors may cause differences between current expectations and actual results, including the potential for Dr. Thompson to determine not to serve as a consultant to the Company.
Departing: Z. Thompson
On April 27, 2026, Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, informed Acadia Pharmaceuticals Inc. (the "Company") of her planned retirement.
- Departure Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
- Dr. Thompson has decided to retire for personal reasons.
- She has committed to continuing in her role as Head of Research and Development for a transitional period until a successor is appointed, after which she intends to remain with the Company as a consultant through the end of 2026, including through the planned readout of the Company's Phase 2 clinical study of remlifanserin in Alzheimer's disease psychosis.
- The Company has initiated a search for Dr. Thompson's replacement.
Tools for this story
Each opens in a new tab, filled in for Acadia Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.